Prognostic value of miR-106b expression in breast cancer patients

Abstract Background The aim of the present study was to evaluate whether the level of expression of tissue or plasma miR-106b can be used to predict clinical outcomes in breast cancer patients. Methods Both tissue and plasma samples were collected and analyzed from 173 patients with primary breast cancer and a set of 50 women with fibroadenoma. The relative expression levels of miR-106b were determined using real-time quantitative reverse transcription polymerase chain reaction and in situ hybridization. Results The levels of miR-106b were upregulated in both tissue and plasma samples from breast cancer patients. The expression levels showed a linear correlation ( rs = 0.748, P